Aurora Cannabis Inc. reported Q1 2025 financial results, achieving positive free cash flow of $6.5 million. Net revenue increased 12% year-over-year to $83.4 million, driven by 13% growth in medical cannabis revenue to $47.2 million. Adjusted EBITDA improved to $4.9 million from $2.6 million last year.The company maintained a strong balance sheet with $182.0 million in cash and cash equivalents. Adjusted gross margin before fair value adjustments on cannabis net revenue was 53%. Aurora continued to focus on its medical cannabis business, which delivered 92% of adjusted gross profit before fair value adjustments.CEO Miguel Martin stated, "Our Q1 results demonstrate continued progress towards sustainable profitability and positive cash flow. Our leading medical cannabis business provides a strong foundation as we pursue growth opportunities in international markets." The company reaffirmed its expectation to achieve positive free cash flow in calendar 2024.

Aurora Cannabis Inc. reported Q1 2025 financial results, achieving positive free cash flow of $6.5 million. Net revenue increased 12% year-over-year to $83.4 million, driven by 13% growth in medical cannabis revenue to $47.2 million. Adjusted EBITDA improved to $4.9 million from $2.6 million last year.The company maintained a strong balance sheet with $182.0 million in cash and cash equivalents. Adjusted gross margin before fair value adjustments on cannabis net revenue was 53%. Aurora continued to focus on its medical cannabis business, which delivered 92% of adjusted gross profit before fair value adjustments.CEO Miguel Martin stated, "Our Q1 results demonstrate continued progress towards sustainable profitability and positive cash flow. Our leading medical cannabis business provides a strong foundation as we pursue growth opportunities in international markets." The company reaffirmed its expectation to achieve positive free cash flow in calendar 2024.